001     842478
005     20220930130139.0
024 7 _ |a 10.3233/JAD-170775
|2 doi
024 7 _ |a 2128/18617
|2 Handle
024 7 _ |a pmid:29578479
|2 pmid
024 7 _ |a WOS:000430016100011
|2 WOS
024 7 _ |a altmetric:35033491
|2 altmetric
037 _ _ |a FZJ-2018-00703
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Dunkelmann, Tina
|0 P:(DE-Juel1)145867
|b 0
245 _ _ |a Comprehensive characterization of the pyroglutamate Aβ induced motor neurodegenerative phenotype of TBA2.1 mice
260 _ _ |a Amsterdam
|c 2018
|b IOS Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1569575861_21918
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Alzheimer’s disease (AD) is the most common neurodegenerative disorder and is being intensively investigated using a broad variety of animal models. Many of these models express mutant versions of human amyloid-β protein precursor (AβPP) that are associated with amyloid-β protein (Aβ)-induced early onset familial AD. Most of these models, however, do not develop bold neurodegenerative pathology and the respective phenotypes. Nevertheless, this may well be essential for their suitability to identify therapeutically active compounds that have the potential for a curative or at least disease-modifying therapy in humans. In this study, the new transgenic mouse model TBA2.1 was explored in detail to increase knowledge about the neurodegenerative process induced by the presence of pyroglutamate modified human Aβ3-42 (pEAβ3-42). Analysis of the sensorimotor phenotype, motor coordination, Aβ pathology, neurodegeneration, and gliosis revealed formation and progression of severe pathology and phenotypes including massive neuronal loss in homozygous TBA2.1 mice within a few months. In contrast, the start of a slight phenotype was observed only after 21 months in heterozygous mice. These data highlight the role of pEAβ3-42 in the disease development and progression of AD. Based on the findings of this study, homozygous TBA2.1 mice can be utilized to gain deeper understanding in the underlying mechanisms of pEAβ3-42 and might be suitable as an animal model for treatment studies targeting toxic Aβ species, complementary to the well described transgenic AβPP mouse models.
536 _ _ |a 573 - Neuroimaging (POF3-573)
|0 G:(DE-HGF)POF3-573
|c POF3-573
|f POF III
|x 0
536 _ _ |a 553 - Physical Basis of Diseases (POF3-553)
|0 G:(DE-HGF)POF3-553
|c POF3-553
|f POF III
|x 1
700 1 _ |a Schemmert, Sarah
|0 P:(DE-Juel1)165908
|b 1
|u fzj
700 1 _ |a Honold, Dominik
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Teichmann, Kerstin
|0 P:(DE-Juel1)164429
|b 3
700 1 _ |a Butzküven, Elke
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Demuth, Hans-Ulrich
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Shah, N. J.
|0 P:(DE-Juel1)131794
|b 6
|u fzj
700 1 _ |a Langen, Karl-Josef
|0 P:(DE-Juel1)131777
|b 7
|u fzj
700 1 _ |a Kutzsche, Janine
|0 P:(DE-Juel1)159137
|b 8
|u fzj
700 1 _ |a Willbold, Dieter
|0 P:(DE-Juel1)132029
|b 9
|e Corresponding author
|u fzj
700 1 _ |a Willuweit, Antje
|0 P:(DE-Juel1)144347
|b 10
|e Corresponding author
|u fzj
773 _ _ |a 10.3233/JAD-170775
|0 PERI:(DE-600)2070772-1
|n 1
|p 115-130
|t Journal of Alzheimer's disease
|v 63
|y 2018
|x 1387-2877
856 4 _ |u https://juser.fz-juelich.de/record/842478/files/P20180162%20%28002%29.pdf
856 4 _ |u https://juser.fz-juelich.de/record/842478/files/Comprehensive%20characterization%20of%20the%20pyroglutamate%20A%CE%B2%20induced%20motor%20neurodegenerative%20phenotype%20of%20TBA2_1%20mice.pdf
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/842478/files/P20180162%20%28002%29.gif?subformat=icon
|x icon
856 4 _ |u https://juser.fz-juelich.de/record/842478/files/P20180162%20%28002%29.jpg?subformat=icon-1440
|x icon-1440
856 4 _ |u https://juser.fz-juelich.de/record/842478/files/P20180162%20%28002%29.jpg?subformat=icon-180
|x icon-180
856 4 _ |u https://juser.fz-juelich.de/record/842478/files/P20180162%20%28002%29.jpg?subformat=icon-640
|x icon-640
856 4 _ |u https://juser.fz-juelich.de/record/842478/files/P20180162%20%28002%29.pdf?subformat=pdfa
|x pdfa
856 4 _ |u https://juser.fz-juelich.de/record/842478/files/Comprehensive%20characterization%20of%20the%20pyroglutamate%20A%CE%B2%20induced%20motor%20neurodegenerative%20phenotype%20of%20TBA2_1%20mice.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:842478
|p openaire
|p open_access
|p OpenAPC
|p driver
|p VDB
|p openCost
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)145867
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)165908
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)164429
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-HGF)0
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)131794
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 7
|6 P:(DE-Juel1)131777
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 8
|6 P:(DE-Juel1)159137
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 9
|6 P:(DE-Juel1)132029
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 10
|6 P:(DE-Juel1)144347
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-573
|2 G:(DE-HGF)POF3-500
|v Neuroimaging
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
913 1 _ |a DE-HGF
|b Key Technologies
|l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences
|1 G:(DE-HGF)POF3-550
|0 G:(DE-HGF)POF3-553
|2 G:(DE-HGF)POF3-500
|v Physical Basis of Diseases
|x 1
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2018
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J ALZHEIMERS DIS : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)ICS-6-20110106
|k ICS-6
|l Strukturbiochemie
|x 0
920 1 _ |0 I:(DE-Juel1)INM-4-20090406
|k INM-4
|l Physik der Medizinischen Bildgebung
|x 1
920 1 _ |0 I:(DE-82)080010_20140620
|k JARA-BRAIN
|l JARA-BRAIN
|x 2
920 1 _ |0 I:(DE-Juel1)INM-11-20170113
|k INM-11
|l Jara-Institut Quantum Information
|x 3
980 1 _ |a APC
980 1 _ |a FullTexts
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)ICS-6-20110106
980 _ _ |a I:(DE-Juel1)INM-4-20090406
980 _ _ |a I:(DE-82)080010_20140620
980 _ _ |a I:(DE-Juel1)INM-11-20170113
980 _ _ |a APC
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)IBI-7-20200312


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21